After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.
Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback